Evidence map›Paper›PMID 41925908›Full record

ReviewSeminars in immunopathology2026

Effect of the intestinal microbiota on T

Justus Neuendorff, Samuel Huber, Penelope Pelczar

Abstract readReview
In one paragraph

Review in Seminars in immunopathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Justus NeuendorffDepartment of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Samuel HuberDepartment of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Penelope PelczarDepartment of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. p.pelczar@uke.de.ORCID 0000-0001-7868-0024

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammatory bowel disease (IBD) is a chronic and relapsing inflammatory condition of the gastrointestinal tract (GI tract). Despite extensive research, its exact pathogenesis remains elusive. However, multiple factors are thought to be involved in the onset and progression of IBD. Aside from genetic risk factors, microbial dysbiosis, environmental cues, defects in the epithelial barrier, as well as a dysregulated intestinal immune response, are critical players driving a vicious cycle, which ultimately results in chronic disease. An orchestrated interaction between the intestinal microbiota and the immune response, especially TH17 cells, is critical for maintaining and re-establishing intestinal homeostasis. Nonetheless, a misguided interaction contributes to the pathogenesis of IBD. Indeed, depending on the microenvironment, intestinal TH17 cells possess dual properties. Either they act to control the inflammatory response, or they acquire pro-inflammatory features promoting the development of intestinal pathology. This context-dependent phenotype of TH17 cells has recently been associated with the microbiota composition, which shapes the inflammatory milieu of the gut. To establish precision immunomodulation as a therapeutic strategy for patients with IBD, it is critical to understand how intestinal microorganisms are involved in actively directing the dichotomous nature of TH17 cells and their cytokine products.

Indexed as

CytokinesGastrointestinal MicrobiomeInflammatory Bowel DiseasesTh17 CellsAnimalsDisease SusceptibilityHumansInflammationInflammation MediatorsIntestinal MucosaIntestinesT-Lymphocyte SubsetsCytokinesInflammation MediatorsInflammatory bowel diseaseIntestinal microbiotaMucosal immunityTH17 cells

Identifiers

PMID41925908
PMCPMC13046662

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.